DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Minneapolis, MN, US. The stock last traded at $6.87, up 3.31% on the session, giving a market capitalisation of $370.2M. On trailing twelve-month figures it carries a trailing P/E of -9.54, a net margin of 0.0%. Its beta of 0.97 implies it has historically moved less than the broad market.
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
DiaMedica Therapeutics Inc. is most often compared with the following Healthcare names: